Overall rank by patents
#30,382
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 10 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
The verdict
Terran holds 9 US patents across 10 technology areas, rank #30,382 of 50,000 tracked assignees.
Terran Biosciences Inc. has been granted 9 US utility patents between 2023 and 2025, placing Terran Biosciences Inc. at rank #30,382 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.8 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Terran Biosciences Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Terran sits between Telling Industries, Llc (9 patents, rank #30,378) and Tetracore, Inc. (9 patents, rank #30,386) - the closest US assignees by grant volume. The composite Innovation Score of 54.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Terran Biosciences Inc.'s 24.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Terran Biosciences Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Telling Industries, LLC
9 patents
Tempus Ex Machina, Inc.
9 patents
Tenaris Connections Limited
9 patents
TeneoBio, Inc.
9 patents
Tescan Brno s.r.o.
9 patents
Tesseract Health, Inc.
9 patents
Test Rite International Co., Ltd.
9 patents
Tetracore, Inc.
9 patents
Terran Biosciences Inc.
9 patents
What this shows Terran holds 9 patents at rank #30,382, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #30,382 in granted patent volume.
Other assignees with the most granted patents in Terran's primary technology class.
Terran's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 2 | 22.2% |
| 2024 | 4 | 44.4% |
| 2025 | 3 | 33.3% |
Top 10 of 10 technology areas
Overall rank by patents
#30,382
Across all tracked assignees
54.0 out of 100
How to use this portfolio
Terran's 9 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.